Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Santen Begins Trials with Oakwood Technology | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Santen Begins Trials with Oakwood Technology

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Santen Pharmaceutical Co., Ltd., of Osaka, Japan has begun Phase I/IIa trials of DE-102, its steroidal treatment for macular edema, employing Oakwood Laboratories’ Chroniject™ sustained release delivery technology. The product’s microsphere formulation and its sterile filling was accomplished at Oakwood’s Cleveland manufacturing facility.

“Oakwood is very pleased to have been able to solve some difficult technical issues in order to bring this product to commercial manufacturing scale, and to the point of clinical use,” said Mark Smith, Oakwood’s president. “We look forward to the continued development of this product.”

According to Mr. Smith, the company’s Chroniject technology has been shown to offer an adaptable and easily scaleable system for the development and manufacture of injectable sustained release dosage forms of multiple drug classes.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters